Synthesis and biological evaluation of 3-aminopyrrolidine derivatives as CC chemokine receptor 2 antagonists.

doi:10.1016/j.bmcl.2010.02.072

Paper

DOI: 10.1016/j.bmcl.2010.02.072

Synthesis and biological evaluation of 3-aminopyrrolidine derivatives as CC chemokine receptor 2 antagonists.

Published Apr 1, 2010 · J. Lim, Youna Oh, Jong-Hoon Kim

Bioorganic & medicinal chemistry letters

Q2 SJR score

Citations

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Study Snapshot

Piperidine compound 19 and piperazine compounds 42, 47, and 49 show highly potent hCCR2 antagonistic activity.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Full text analysis coming soon...

References

DOI: 10.1161/ATVBAHA.108.179705

Inflammation in Atherosclerosis

Inflammation plays a crucial role in atherosclerosis, linking dyslipidaemia to atheroma formation and promoting thrombosis, offering a mechanistic framework for understanding the clinical benefits of lipid-lowering therapies.

2012·9705citations·P. Libby·Arteriosclerosis, Thrombosis, and Vascular Biology

Arteriosclerosis, Thrombosis, and Vascular Biology

DOI: 10.1016/j.bmcl.2008.12.050

Design, synthesis, and structure-activity relationship of novel CCR2 antagonists.

Novel CCR2 antagonists, such as analog 59, show potent antagonistic activity against the human receptor.

2009·24citations·S. Kothandaraman et al.·Bioorganic & medicinal chemistry letters

Bioorganic & medicinal chemistry letters

DOI: 10.1016/j.bmcl.2008.05.010

Substituted dipiperidine alcohols as potent CCR2 antagonists.

Substituted dipiperidine alcohols show potent CCR2 antagonist activity with nanomolar or subnanomolar IC 50 values, and cinnamoyl compounds show higher binding affinities than urea analogs.

2008·12citations·Mingde Xia et al.·Bioorganic & medicinal chemistry letters

Bioorganic & medicinal chemistry letters

DOI: 10.1016/j.bmcl.2008.02.015

Potent antagonists of the CCR2b receptor. Part 3: SAR of the (R)-3-aminopyrrolidine series.

This study identified several potent CCR2b antagonists with strong binding and functional activity, potentially useful for therapeutic applications.

2008·24citations·W. J. Moree et al.·Bioorganic & medicinal chemistry letters

Bioorganic & medicinal chemistry letters

DOI: 10.1016/J.DDSTR.2006.07.003

Chemokines and chemokine receptors: Large and small therapeutic strategies for inflammatory diseases

Chemokines and their receptors are attractive therapeutic targets for immune-mediated inflammatory diseases, with both small and large molecule therapeutics in development.

2006·8citations·Anuk M. Das et al.·Drug Discovery Today: Therapeutic Strategies

Drug Discovery Today: Therapeutic Strategies

Citations

DOI: 10.1080/00397911.2018.1509093

Economical synthesis of tert-butyl (S)-3-aminopyrrolidine-1-carboxylate from L-aspartic acid

This study presents an economical, readily available, and easy-to-work-up method for synthesizing (S)-tert-butyl-3-aminopyrrolidine-1-carboxylate from L-aspartic acid, offering potential for industrial preparation.

2018·2citations·Zhi-Jian Han et al.·Synthetic Communications

Synthetic Communications

DOI: 10.1007/s12272-016-0748-2

Pharmacokinetics of YJC-10592, a novel chemokine receptor 2 (CCR-2) antagonist, in rats

YJC-10592 has dose-dependent pharmacokinetics and low bioavailability due to slower elimination and incomplete absorption, making it a potential treatment for asthma and atopic dermatitis.

2016·4citations·E. Du et al.·Archives of Pharmacal Research

Archives of Pharmacal Research

DOI: 10.1517/13543776.2013.771168

Progress in the discovery of CC chemokine receptor 2 antagonists, 2009 – 2012

CCR2 antagonist discovery has made significant progress, with progress in selectivity, cardiac safety, and preclinical pharmacokinetics, but establishing proof-of-concept in clinical trials remains the primary challenge.

2013·36citations·P. Carter·Expert Opinion on Therapeutic Patents

Expert Opinion on Therapeutic Patents

DOI: 10.1016/j.bmc.2011.06.030

Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors.

Novel class I HDAC inhibitors show isoform selectivity by exploiting the internal acetate release channel, potentially revealing insights into enzyme function through novel structural features.

2011·142citations·L. Whitehead et al.·Bioorganic & medicinal chemistry

Bioorganic & medicinal chemistry

DOI: 10.1007/s00894-010-0943-x

Ligand supported homology modeling and docking evaluation of CCR2: docked pose selection by consensus scoring

Ligand supported homology modeling and consensus scoring can effectively identify new CCR2 antagonists by screening a large database of compounds.

2011·21citations·Jong-Hoon Kim et al.·Journal of Molecular Modeling

Journal of Molecular Modeling